Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I don't blame you F2 ... ;)
smart move buddy !!!
So 5.6 million shares changed hands because bozo the clown honked his horn and now an ambulance chaser has put up a sign ... don't know about the rest of you but I bought 3,500 more shares today at prices I never thought we would see again.
The SEC needs to get off their backsides and go after the circus monkeys that are responsible for this b.s. Hope everybody lets them hear from you ... as frobinso said this morning .. the more that contact them about this smear job the better chance we have of something being done.
I do not mind buying cheaper shares but, when it happens this way it is total B.S.
I do admit though, I am curious how many funds and institutions bought in a big way today ... we will have to wait and see, but many shares went to stronger hands today in my opinion.
John
Exactly frobinso ... the more the better. This is about the worst I have seen and that is bad. It reminds me of some of the garbage that was thrown at IDCC years ago, but this one is worse and it needs to be reported.
I have got some choice words for them but I will get kicked off permanently if I use them ... BUT I think all of you know what I and thinking !!!
SHORT ATTACK ...
Kerrisdale Capital
@KerrisdaleCap
We're short $LWLG. Report available at http://kerr.co/lwlg. Lightwave Logic is a photonic device company that's been stuck in "development stage" for 30 years, and will probably never come out. (1/8)
9:43 AM · Jun 2, 2022·Twitter Web App
6
Retweets
2
Quote Tweets
10
Likes
Kerrisdale Capital
@KerrisdaleCap
·
2m
Replying to
@KerrisdaleCap
Lightwave says its electro-optic polymers and optical modulators will enable 2-3x faster internet speeds, but it's been saying that since it went public in 2007. In the meantime, optical transmission speeds have increased >20x and $LWLG has generated zero revenue. (2/8)
Kerrisdale Capital
@KerrisdaleCap
·
1m
Lightwave's claims are not even impressive. The modulators it supposedly tested in its labs run at slower data speeds than what's commercially available, and the power consumption specs are irrelevant for modern transceivers using advanced DSP functionality. (3/8)
Kerrisdale Capital
@KerrisdaleCap
·
1m
Worst of all, former $LWLG employees confirmed that Lightwave has no way to consistently and repeatably manufacture the underlying EO polymers due to the fraught nature of electrical poling, which is a critical process in the fabrication of the polymer. (4/8)
Kerrisdale Capital
@KerrisdaleCap
·
29s
In other words, any polymer or device that $LWLG claims to have developed, built, and tested is just a one-off production that can't be replicated consistently. (5/8)
??_DD
@afroeeee
·
1m
Replying to
@KerrisdaleCap
Sounds like $akp on #ASX
drunk or sober ... it would be something to behold ... AMC ... Gamestop ... Reddit crews worked against all odds that they could pull it off.
The difference is with LWLG we would be backing a bonafied winner with staying power and a support base of shareholders with a real belief in what Lightwave is and will be.
As they say ... " it would be a thing of beauty to behold " ... we can dream anyway.
F2 ... agree and I think we have a lot more of this ahead of us ... when we look at who the institutions and funds are that have already gotten their feet wet ... I keep thinking ... and this ... is only the beginning ... ;)
... and that has worked for those of us that have been adding to our position at these low prices. The truth that matters the most here is that when we get to discuss a 2 miillion share purchase that someone wanted bad enough to put $ 16 million on the table ... that is serious money for a serious player.
The MM's don't put the 2 million qty. totally out there at one time for that very reason. The MM's control the flow of the market. They pick up the shares throughout the entire trading day.
Also, they know what the client wants and cherry picks throughout the trading day. The client has his range that is acceptable and he does not care if the total number he wants is accummulated in one day or several, as long as they are picked up in his target price range.
Also, there are also pre-arranged sells and buys that are put together by the MM's.
If a fund or institution wants to buy or sell a large qty. of shares they do not throw 2 million shares out on the open market themselves and never at one time.
jmho and there are more variables than any of us are prevy to ...
Those are acculative orders purchase on behalf of a fund or institution throughout the course of the trading day by the Market Makers. They give them a range of the prices they are willing to pay for the total quantity and the MM's fill the order during that session. The total is provided at the end of the session, as is the case for the 1,979,624 number ... jmho
Amen ... ;)
GREAT summary KCCO ... THANK YOU !!!
... the real deal that no one will be able to resist ... when the word spreads so will the price ... we don't even know the limits that await us ... but, if correct, we will not have to wait long for a price correction north..... ;)
Glad to see this Rkf !!!
Hopefully it is just the start !!!
THANKS,
John
... ;)
Thumbs up Scope !!!
Garbage post ... total trash
crmar this is a good article ... thanks for posting it !!!
https://www.yahoo.com/news/poet-could-poet-biggest-market-102000927.html
Agree with you ... honestly with as few shares that are traded the 2.5% of the float is actually good ... ;)
LOVE IT ROBERT !!! ... ;)
The following is just my opinion:
I have never understood why anyone for any stock that has a site on Investor Hub, is allowed to go to that site or any other and repeatedly claim that a stock is a scam.
It goes against the principles of common sense that they would be allowed to do so.
jmho
A few more institutional buyers :
https://fintel.io/so/us/poet
Only 2.5% of the total float but, we got to start somewhere ... ;)
Wow, we get all of your 10 posts since you joined 6 days ago ... short much ?
THANKS Loop !!! Great post and very informative from someone that actually knows the subject matter and how it works.
Great to see you Loop and hope you and the family are well,
John
Zacks SCR
@ZacksSmallCap
$POET $PTK.V POET Technologies Adds Mulitple Customers and Expects to Start Production Volumes By Year End #technology #photonics - https://bit.ly/3kU1Nqj
From Agoracom POET site:
https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/778195-may-the-best-technology-win/messages/2357008#message
A couple of interesting pointsTom made: It's been only since January that we have, after over four years of development, been able to deliver samples to customers. These beta samples are important because they meet spec and they are the ones that customers will use for reliability testing which takes you know about, couple of months, three to six months in some cases.
We're sending out samples to as many companies as we possibly can as soon as we possibly can. And the beta units are largely expected to start sampling here this month.
And Tom mentioned they have already performed 5,000 hours of reliability testing internally and based on what they see they are confident that the samples will pass the customers testing.
I think that there is a high level of expectation for a very big acceptance of the platform by those that are receiving the samples.
And the longer these companies wait the bigger the line will grow for products IMO so I think many will be inspired to fast track their acceptance testing.
From Presentation Today: Active Customer Engagements
posted on May 12, 2022 01:05PM
Log in to use the IP Check tool [?]
POET’s Active Customer Engagements
Posted on Agoracom : https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/778198-from-presentation-today-active-customer-engagements/messages/2356994#message
Customer A: Systems Company: 100G CWDM4/LR4 optical engines: under contract: design–in Q3 ’22: production Q4 ’22: 20 million 3-year projection.
Customer B: Machine Learning Company: LightBar: under contract: design-in 1H ’23: production 2H ’23: 100 million 3-year projection.
Customer C: Module Company: 100G CWDM4 Optical Engines: Committed: Design-in Q3 ’22: Production Q4 ’22: 5 million 3-year projection.
Customer D: Module Company: 100G/200G/400G Optical Engines: Committed: Design-in 2H ’22: Production: 1H 2023: 30 million 3-year projection.
Customer E: Module Company: 200G/400G Optical Engines: Engaged: Design-in 2H ’22: Production 1H ’23: 25 million 3-year projection.
Customer F: Module Company: 200G/400G Optical Engines: Engaged: Design-in 2H ’22: Production 1H ’23: 25 million 3-year projection.
Customer G: Data Center (!): LightBar: Engaged: Design-in 1H ’23: Production 2H ’23: 50 million 3-year projection.
Customer H: Optical I/O system: LightBar: Engaged: Design-in 1H ’23: Production 2H ’23: 15 million 3-year projection.
Just with these companies, 270 million 3-year projection
51 Recommendations
VALENCIA, Calif. and MELBOURNE, Australia, May 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its first quarter ended March 31, 2022.
Financial Highlights and Recent Updates:
Reported commercial revenue, which excludes BARDA revenue, of $7.4 million a 61% increase compared to $4.6 million in the corresponding period in the prior year
Reported total revenue, which includes BARDA revenue, of $7.5 million compared to $8.8 million in the corresponding period in the prior year, which included $4.1 million in BARDA revenue
In February 2022, FDA approved our premarket approval application (PMA) supplement for RECELL® Autologous Cell Harvesting Device, an enhanced RECELL system aimed at providing clinicians a more efficient user experience and simplified workflow
In February 2022, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved our application for commercialization of the RECELL system in burns
As of March 31, 2022, the Company had $95.0 million in cash, cash equivalents, and marketable securities, with no debt
“Our commercial team performed well this quarter driving further adoption and penetration within burn centers, and our clinical team continued to move the soft tissue reconstruction and vitiligo trials forward,” said Dr. Mike Perry, AVITA Medical Chief Executive Officer. “We are well positioned to drive revenue growth ahead and we look forward to topline data readouts from our soft tissue reconstruction and vitiligo clinical trials in the second half of this year.”
First Quarter of Year 2022 Financial Results
Our commercial revenue, which excludes BARDA revenue, was $7.4 million in the current year, an increase of $2.8 million or 61%, compared to $4.6 million the corresponding period in the prior year. Total revenue, which includes BARDA revenue, was $8.8 million in the corresponding period in the prior year which included $4.1 million in BARDA related revenue that resulted from our delivery of units to managed inventory for BARDA for emergency response preparedness. The increase in commercial revenue was largely driven by broader utilization among our customer base as well as deeper penetration within individual customer accounts.
Gross profit margin was 76% and is flat compared to the corresponding period in the prior year.
Total operating expenses increased by 21% to $16.0 million compared to $13.2 million in the corresponding period in the prior year. The increase in operating expenses is primarily attributable to higher share-based compensation, salary, and benefits. Higher share-based compensation expenses are associated with acceleration of expense for certain performance milestones being met in the current quarter. Higher salary and benefits are driven by the expansion of our workforce to support the overall operations, an increase in field resources to expand our market coverage and hiring of an executive at the end of March 2021.
Net loss increased by 58% or $3.5 million to $9.5 million, or $0.38 per share, compared to a net loss of $6.0 million, or $0.26 per share, in the corresponding period of the prior year.
Adjusted EBITDA* loss increased by 42%, or $1.9 million to $6.4 million, over the $4.5 million recognized in the corresponding period in the prior year. A table reconciling non-GAAP measures is included in this press release for reference.
Calendar Year 2022 Revenue Guidance
Commercial revenues in calendar year 2022 are projected to be approximately $30 million, excluding BARDA revenues, which represents a 20% increase year-over year. We project BARDA revenues of approximately $0.3 million in calendar year 2022, as compared to $7.9 million in calendar year 2021, since we completed delivery of RECELL units into the national stockpile in 2021.
*Adjusted EBITDA is a non-GAAP financial measure. See the appendix to this release for a discussion of Non-GAAP financial measures, including a reconciliation to the most closely correlated GAAP measure.
Webcast and Conference Call Information
The Company will host a conference call to discuss the first quarter financial results after market close on Thursday May 12, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time (being 6.30 a.m. Australian Eastern Standard Time on Friday May 13, 2022). The conference call can be accessed live over the phone at (833) 614-1538 for U.S. callers or at (706) 634-6548 international callers, using conference ID:2592487. The live webinar can be accessed at https://ir.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
ABOUT AVITA Medical, Inc.
AVITA Medical, Inc. is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical Inc. patented, and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.
AVITA Medicals’ first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is approved for acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.
In February 2022, the FDA reviewed and approved the PMA supplement for RECELL Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow. The RECELL System is a device that enables healthcare professionals to produce a suspension of Spray-On Skin™ Cells using a small sample of the patient’s own skin for the treatment of acute thermal burns
In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.
To learn more, visit www.avitamedical.com.
* Use of Non-GAAP Measure
AVITA Medical’s reported earnings are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the Securities and Exchange Commission. AVITA Medical has provided in this release certain financial information that has not been prepared in accordance with GAAP. AVITA Medical’s management believes that the non-GAAP adjusted EBITDA described in the release, which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding AVITA Medical’s underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in AVITA Medical’s industry. However, the non-GAAP financial measures that AVITA Medical uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational, and financial goals. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions including, but not limited to the ongoing COVID-19 pandemic which are outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements
TORONTO, Ontario, May 11, 2021 – POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, today reported its unaudited condensed consolidated financial results for the first quarter ended March 31, 2022. The Company’s financial results as well as the Management Discussion and Analysis have been filed on SEDAR. All financial figures are in United States dollars (“USD”) unless otherwise indicated.
First Quarter Financial (non-IFRS) and Recent Business Highlights:
The Company achieved the following significant milestones during the three months ended March 31, 2022:
Named to the 2022 OTCQX® Best 50, a ranking of top performing companies traded on the OTCQX Best Market last year.
Entered into an agreement with Celestial AI to provide multi-laser integrated external light source (ELS) modules using its advanced packaging platform based on the POET Optical Interposer. The agreement includes a contract for continued platform development, along with a purchase order for initial quantities of the advanced modules.
Announced a collaboration with Liobate Technologies to incorporate advanced Thin-Film Lithium Niobate (“TFLN”) modulators onto POET’s Optical Engines supporting power-efficient ultra-high-bandwidth electro-optic conversion for data center and telecom applications. This multi-phase, co-development project is initially focused on delivering and commercializing a POET 400/800Gps Transmit and Receive Optical Engine.
Announced the launch of its 400G FR4 and 800G (2x400G FR4) Receive (RX) Optical Engines based on the POET Optical Interposer, a unique next-generation hybrid silicon photonics platform.
Completed previously announced consolidation of its common shares and commenced trading on Nasdaq under the ticker symbol “POET”.
Joined the Singapore Hybrid-Integrated Next Generation micro-Electronics (SHINE) Center located in the College of Design and Engineering at the National University of Singapore (NUS).
Management Comments
“The first quarter has been an active period of sampling and expanding customer engagement,” stated Dr. Suresh Venkatesan, Chairman & CEO. “We were able to leverage our success at OFC where we demonstrated our 200G FR4 Transmit and 400G FR4 Receive optical engines. POET received significant notoriety for being the only company to showcase a chip-scale integrated FR4 optical engine, offering substantial size, energy efficiency and cost benefits compared to alternative solutions based on the DR4 standard, resulting in heightened interest from companies that we have not been engaged with previously. We are focused on advancing our efforts to convert this interest to customer orders in the coming quarters.”
Financial Summary
The Company reported a net loss of $5.4 million, or ($0.15) per share, in the first quarter of 2022 compared with a net loss $4.1 million, or ($0.13) per share, for the same period in 2021 and a net loss of $3.7 million, or ($0.10) per share, in the fourth quarter of 2021. The net loss in the first quarter of 2022 included research and development costs of $2.2 million compared to $1.3 million for the same period in 2021 and $2.0 million in the fourth quarter of 2021. The Company added engineering headcount as its product development and new product introduction efforts expanded. The Company also engaged with new suppliers, through non-recurring engineering and qualification programs, to ensure that the supply of required products and services will meet the Company’s standards and will be available as needed.
Non-cash expenses in the first quarter of 2022 included stock-based compensation of $1.0 million and depreciation and amortization of $0.3 million. Non-cash stock-based compensation and depreciation and amortization in the same period of 2021 were $0.8 million and $0.3 million, respectively. Fourth quarter 2021 stock-based compensation and depreciation and amortization were $1.2 million and $0.3 million, respectively. The Company had debt-related finance costs of $14,000 in the first quarter of 2022 compared to $235,000 in the first quarter of 2021 and $16,000 in the fourth quarter of 2021. All of the finance costs recognized in the first quarter of 2022 were non-cash compared to $128,000 during the same period in 2021 and $16,000 in the fourth quarter of 2021. The Company recognized other income, including interest of $22,000 in the first quarter of 2022 compared to $7,000 in the same period in 2021 and $27,000 in the fourth quarter of 2021.
Non-cash impact of joint venture in the first quarter of 2022 was $0.4 million compared to nil in the same period of 2021 and $1.0 million in the fourth quarter of 2021. The Company’s share of loss is approximately 88.5% of the loss of Super Photonics Xiamen, the Company’s joint venture with Sanan IC. The Company's current share of the operating loss is a result of the high value of the Company's initial contribution.
Cash flow from operating activities in the first quarter of 2022 was ($3.7) million compared to ($2.5) million in the first quarter of 2021 and ($3.2) million in the fourth quarter of 2022.
Non-IFRS Financial Performance Measures
Certain financial information presented in this press release is not prescribed by IFRS. These non-IFRS financial performance measures are included because management has used the information to analyze the business performance and financial position of POET. These non-IFRS financial measures are intended to provide additional information only and do not have any standardized meaning under IFRS and may not be comparable to similar measures presented by other companies. These non-IFRS financial measures should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS.
POET TECHNOLOGIES INC.
PROFORMA – NON-IFRS PRESENTATION OF OPERATIONS
(All figures are in U.S. Dollars)
For the Quarter ended:
31-Mar-22
31-Dec-21
30-Sep-21
30-Jun-21
31-Mar-21
Sales
-
-
-
209,100
Research and development
(2,232,534)
(2,010,793)
(1,231,676)
(1,812,924)
(1,339,784)
Depreciation and amortization
(302,018)
(281,178)
(296,424)
(270,189)
(252,731)
Professional fees
(248,112)
(269,306)
(354,163)
(247,742)
(284,105)
Wages, benefits and management fees
(608,518)
(610,428)
(623,731)
(593,280)
(816,012)
Impact of joint venture
(430,321)
1,022,417
422,834
-
-
Stock-based compensation
(997,441)
(1,181,375)
(1,295,864)
(1,236,593)
(820,538)
General expenses and rent
(622,060)
(377,223)
(275,078)
(381,539)
(357,980)
Interest expense
(13,794)
(15,512)
(19,729)
(94,799)
(234,579)
Other income, including interest
21,999
26,650
208,100
19,772
7,309
Net loss
(5,432,799)
(3,696,748)
(3,465,731)
(4,408,194)
(4,098,420)
Net loss per share
(0.15)
(0.10)
(0.10)
(0.13)
(0.13)
About POET Technologies Inc.
POET Technologies is a design and development company offering integration solutions based on the POET Optical Interposer™ a novel platform that allows the seamless integration of electronic and photonic devices into a single multi-chip module using advanced wafer-level semiconductor manufacturing techniques and packaging methods. POET’s Optical Interposer eliminates costly components and labor-intensive assembly, alignment, burn-in and testing methods employed in conventional photonics. The cost-efficient integration scheme and scalability of the POET Optical Interposer brings value to any device or system that integrates electronics and photonics, including some of the highest growth areas of computing, such as Artificial Intelligence (AI), the Internet of Things (IoT), autonomous vehicles and high-speed networking for cloud service providers and data centers. POET is headquartered in Toronto, with operations in Allentown, PA and Singapore. More information may be obtained at www.poet-technologies.com.
Shareholder Contact:
Shelton Group
Brett L. Perry
sheltonir@sheltongroup.com
Company Contact:
Thomas R. Mika, EVP & CFO
tm@poet-technologies.com
This news release contains “forward-looking information” (within the meaning of applicable Canadian securities laws) and “forward-looking statements” (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “potential”, “estimate”, “propose”, “project”, “outlook”, “foresee” or similar words suggesting future outcomes or statements regarding any potential outcome. Such statements include the Company’s expectations with respect to the success of the Company’s product development efforts, the performance of its products, the expected results of its operations, meeting revenue targets, and the expectation of continued success in the financing efforts, the capability, functionality, performance and cost of the Company’s technology as well as the market acceptance, inclusion and timing of the Company’s technology in current and future products.
Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, management’s expectations regarding the success and timing for completion of its development efforts, financing activities, future growth, recruitment of personnel, opening of offices, the form and potential of its joint venture, plans for and completion of projects by the Company’s third-party consultants, contractors and partners, availability of capital, and the necessity to incur capital and other expenditures. Actual results could differ materially due to a number of factors, including, without limitation, the failure of its products to meet performance requirements, lack of sales in its products, once released, operational risks in the completion of the Company’s anticipated projects, lack of performance of its joint venture, delays in recruitment for its newly opened operations or changes in plans with respect to the development of the Company’s anticipated projects by third-parties, risks affecting the Company’s ability to execute projects, the ability of the Company to generate sales for its products, the ability to attract key personnel, and the ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company’s securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward-looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
120 Eglinton Avenue, East, Suite 1107, Toronto, ON, M4P 1E2- Tel: 416-368-9411 - Fax: 416-322-5075
I contacted the farmer that planted you and he is going to harvest you early because he does not want to risk you rotting in the field.... :)
Four instutional buyers now :
https://www.nasdaq.com/market-activity/stocks/poet/institutional-holdings
RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting
PDF Version
VALENCIA, Calif. and MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that a discussion on the RECELL System will be held during the Symposium for Cosmetic Advances & Laser Education (SCALE) multidisciplinary dermatology meeting taking place May 11-15 in Nashville, TN. SCALE is the premier multidisciplinary meeting for aesthetic medicine, plastic surgery and medical dermatology.
The presentation will feature Dr. Jeffrey Carter, FACS, Associate Professor of Surgery and Medical Director, UMCNO Burn Center at LSU Health in New Orleans, who will discuss the use of the RECELL System for treatment of burn injuries. Additionally, Dr. Seemal Desai, FAAD, Diplomate of the American Board of Dermatology, and a Board-Certified Dermatologist, will review the clinical trial protocol aimed at establishing safety and effectiveness for repigmentation of stable vitiligo lesions utilizing the RECELL System. The discussion, “RECELL: A Novel Treatment Strategy for Regenerative & Restorative Skin Conditions” will take place Thursday, May 12 from 2:30-2:40 pm CDT.
“It is important for us to share clinical evidence and peer insights related to the RECELL System with leaders of the dermatology community to help physicians make educated treatment decisions for their patients,” said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. “As we pursue the vitiligo indication, our vision is to offer the community an innovative solution to better serve the millions of people who suffer with this disease.”
Vitiligo is a disease that attacks pigment-producing cells, called melanocytes, resulting in their destruction or malfunction. The result is a loss of pigmentation in patches of skin. Vitiligo affects up to 2% of the population worldwide,i including an estimated 3-6.5 million Americans.ii Vitiligo has a comparable market size and psychosocial impact to other major dermatology diseases including psoriasis (thick, scaly skin) and atopic dermatitis (red, cracked skin).iiiivv Like these diseases, those living with vitiligo may suffer from poor body image along with low self-esteem, leading to an impaired quality of life.vi
AVITA Medical is currently completing a pivotal trial for the use of the RECELL System for treatment of stable vitiligo. Currently, the RECELL System is indicated in the U.S. for treatment of acute thermal burns. Our vitiligo clinical trial aims to demonstrate safe and effective repigmentation when using the RECELL System in combination with phototherapy. Topline data from the trial will be shared later this year.
ABOUT AVITA MEDICAL, INC.
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.
AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.
In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.
This press release was authorized by the review committee of AVITA Medical, Inc.
Tomorrow is the SIDOTI Conference ...
https://sidoti.zoom.us/webinar/register/WN_rab0PHhqQTGke1AuKbuU_g
Tomorrow is the SIDOTI Conference ...
https://sidoti.zoom.us/webinar/register/WN_rab0PHhqQTGke1AuKbuU_g
Posted on Agoracom by fairchijisback on POET board ...
Suresh on the same stage as Robert Blum @ ECOC Europe
posted on May 04, 2022 11:16AM
Log in to use the IP Check tool [?]
Symposium: Hybrid Integration Technologies (ecoc2022.org)
Also have a listen to Katharine Schmidtke. She basically makes the case for POET in the following presentation.
(98) "Problems Faced by Data Centers Today and Future Needs" - Katharine Schmidtke - YouTube
[tag](98) "Problems Faced by Data Centers Today and Future Needs" - Katharine Schmidtke - YouTube [/tag](98)
I agree Robert ... looking forward to them having more company to ... ;)
This ZACK'S Report by Lisa Thompson might help ...
https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_04282022_POET_Thompson.pdfhttps://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_04282022_POET_Thompson.pdf
POET has 2 institutional investors now :
https://www.nasdaq.com/market-activity/stocks/poet/institutional-holdings